Formulary Watch |

All News - Page 29

CVS Caremark Removes 5 Brands from Drug List
CVS Caremark Removes 5 Brands from Drug List
CVS Caremark Removes 5 Brands from Drug List
February 15, 2023
The branded therapies were removed in favor of generics effective April 2023. CVS Caremark also added 13 generics to its Performance Drug List.
Sen. Cantwell to Hold Hearing on PBMs
Sen. Cantwell to Hold Hearing on PBMs
Sen. Cantwell to Hold Hearing on PBMs
February 14, 2023
The hearing will discuss the role of PBMs in healthcare and the Pharmacy Benefit Manager Transparency Act, legislation that has been submitted by Sens. Maria Cantwell and Chuck Grassley.
Ferring Launches First Microbiome Therapy to Prevent C. Diff Infection
Ferring Launches First Microbiome Therapy to Prevent C. Diff Infection
Ferring Launches First Microbiome Therapy to Prevent C. Diff Infection
February 14, 2023
No list price was provided for Rebyota but Ferring is offering copay and patient assistance programs.
FDA Refuses NDA for Cutaneous T-Cell Lymphoma
FDA Refuses NDA for Cutaneous T-Cell Lymphoma
FDA Refuses NDA for Cutaneous T-Cell Lymphoma
February 14, 2023
The FDA indicated that Soligenix’s application for HyBryte, a novel photodynamic therapy, was incomplete.
FDA Warns About Hospira’s Pediatric Indication on Potassium Phosphates
FDA Warns About Hospira’s Pediatric Indication on Potassium Phosphates
FDA Warns About Hospira’s Pediatric Indication on Potassium Phosphates
February 13, 2023
Hospira/Pfizer’s potassium phosphates product alone may produce daily aluminum exposures of up to twice of the FDA-recommended limit for children.
FDA Grants Priority Review for Linzess in Children, Adolescents
FDA Grants Priority Review for Linzess in Children, Adolescents
FDA Grants Priority Review for Linzess in Children, Adolescents
February 13, 2023
If approved, Linzess would be the first and only FDA-approved prescription therapy for functional constipation in children 6 to 17 years of age. The PDUFA date is June 14th, 2023.
Blackley on the Impact of State PBM Regulations
Blackley on the Impact of State PBM Regulations
Blackley on the Impact of State PBM Regulations
February 13, 2023
Chris Blackley, co-founder and chief executive officer of Prescryptive Health, discusses the laws that states that are implementing to restrict PBM practices and the impact on patients and employers.
FDA Expands Cibinqo Label for Atopic Dermatitis in Adolescents
FDA Expands Cibinqo Label for Atopic Dermatitis in Adolescents
FDA Expands Cibinqo Label for Atopic Dermatitis in Adolescents
February 11, 2023
Cibinqo is an oral, once-daily JAK1 inhibitor now approved for those 12 years of age and older.
3 New, and High-Cost, Gene Therapies are Expected This Year
3 New, and High-Cost, Gene Therapies are Expected This Year
3 New, and High-Cost, Gene Therapies are Expected This Year
February 10, 2023
High-priced gene therapies challenge payers to provide access. They are watching the products to be approved the first half of this year.
FDA Grants Full Approval to Jemperli for Endometrial Cancer
FDA Grants Full Approval to Jemperli for Endometrial Cancer
FDA Grants Full Approval to Jemperli for Endometrial Cancer
February 10, 2023
Conversion from accelerated to regular approval was based on long-term outcomes from a phase 1 trial, which demonstrated an overall response rate of 45.4%.
FDA Approves First Pediatric Indication for Blockbuster Eylea
FDA Approves First Pediatric Indication for Blockbuster Eylea
FDA Approves First Pediatric Indication for Blockbuster Eylea
February 9, 2023
Eylea now also treats retinopathy of prematurity, a leading cause of childhood blindness worldwide.
Study: Lower Rebates, and Lower Prices, Lead to Lower Patient Costs
Study: Lower Rebates, and Lower Prices, Lead to Lower Patient Costs
Study: Lower Rebates, and Lower Prices, Lead to Lower Patient Costs
February 8, 2023
In a real-world example, investigators found that lowered pricing of prescription drugs results in lower patient out-of-pocket costs, particularly for those patients with coinsurance.
CVS Pharmacy Services Revenue up 10.6% for 2022
CVS Pharmacy Services Revenue up 10.6% for 2022
CVS Pharmacy Services Revenue up 10.6% for 2022
February 8, 2023
In 2023, CVS executives expect revenue in pharmacy services to grow by 1% to 2% driven by generic and biosimilar launches.
States, not Federal Government, Are Moving to Tighten Regulation of PBMs
States, not Federal Government, Are Moving to Tighten Regulation of PBMs
States, not Federal Government, Are Moving to Tighten Regulation of PBMs
February 7, 2023
In 2022, 12 states have enacted 19 pieces of legislation that put a variety of restrictions and requirements on pharmacy benefit managers (PBMs).
FDA Sets PDUFA Date for Dry Eye Disease Drug
FDA Sets PDUFA Date for Dry Eye Disease Drug
FDA Sets PDUFA Date for Dry Eye Disease Drug
February 7, 2023
If approved, reproxalap would be the first inhibitor of RASP to treat patients with dry eye disease. The FDA PDUFA date is Nov. 23, 2023.
FDA Okays Pediatric Indication for Takeda’s Takhzyro
FDA Okays Pediatric Indication for Takeda’s Takhzyro
FDA Okays Pediatric Indication for Takeda’s Takhzyro
February 6, 2023
Takhzyro is the first therapy to prevent attacks of hereditary angioedema (HAE) in children ages 2 to under 6.
FDA Accepts NDA for Zuranolone for Depression
FDA Accepts NDA for Zuranolone for Depression
FDA Accepts NDA for Zuranolone for Depression
February 6, 2023
Zuranolone is a rapid-acting neuroactive steroid that can take effect in 14 days to treat patients with major depressive disorder and postpartum depression. The FDA has assigned a PDUFA action date of Aug. 5, 2023.
Credit: CDC/ National Institute of Allergy and Infectious Diseases (NIAID)
FDA Warns Companies Claiming to Treat Monkeypox
FDA Warns Companies Claiming to Treat Monkeypox
February 4, 2023
The products may be ineffective, unsafe and could prevent a person from seeking an appropriate diagnosis.
FDA Approves Trodelvy for HR+/HER2- Breast Cancer
FDA Approves Trodelvy for HR+/HER2- Breast Cancer
FDA Approves Trodelvy for HR+/HER2- Breast Cancer
February 3, 2023
Trodelvy has been recommended as a preferred treatment for metastatic HR+/HER2- breast cancer by the National Comprehensive Cancer Network.
FDA Approves Tezspire in Pre-Filled Pen
FDA Approves Tezspire in Pre-Filled Pen
FDA Approves Tezspire in Pre-Filled Pen
February 3, 2023
Tezspire is a biologic that specifically targets the inflammation associated with asthma.
Cigna’s Evernorth Division Contributed $140 million in 2022 Revenue
Cigna’s Evernorth Division Contributed $140 million in 2022 Revenue
Cigna’s Evernorth Division Contributed $140 million in 2022 Revenue
February 3, 2023
Evernorth, Cigna’s pharmacy and benefits solutions division, contributed more than 75% of the company’s revenue last year.
Will the Biosimilar Amjevita Lower Costs?
Will the Biosimilar Amjevita Lower Costs?
Will the Biosimilar Amjevita Lower Costs?
February 2, 2023
The real impact may not likely be seen until after July when additional biosimilars referencing Humira are launched.
FDA Approves Novel Therapy for CKD-Related Anemia
FDA Approves Novel Therapy for CKD-Related Anemia
FDA Approves Novel Therapy for CKD-Related Anemia
February 2, 2023
Daprodustat, now with the brand name of Jesduvroq, is a new oral therapy but it carries a boxed warning about the risk of cardiovascular events.
Subpotency Leads to Recall of 27 Lots of Tirosint-SOL
Subpotency Leads to Recall of 27 Lots of Tirosint-SOL
Subpotency Leads to Recall of 27 Lots of Tirosint-SOL
February 2, 2023
IBSA Pharma is recalling the hypothyroid medication because analyses showed lowered levels of levothyroxine in some lots.
Daiichi Sankyo Makes Available New Dosing Regimen for Turalio
Daiichi Sankyo Makes Available New Dosing Regimen for Turalio
Daiichi Sankyo Makes Available New Dosing Regimen for Turalio
February 1, 2023
Dosing has been lowered to reduce the risk of liver damage in patients taking Turalio, which is approved to treat patients with a rare tumor that affects the joints.
Hospital Drug Spending to Increase through July 2024
Hospital Drug Spending to Increase through July 2024
Hospital Drug Spending to Increase through July 2024
January 31, 2023
Vizient is forecasting a 3.78% rise in pharmacy prices in hospitals and non-acute care facilities, reflecting increases in both prices and utilization.
First Humira Biosimilar is Now Available
First Humira Biosimilar is Now Available
First Humira Biosimilar is Now Available
January 31, 2023
Some PBMs will offer Amgen’s Amjevita biosimilar as a preferred product alongside Humira, but CVS Caremark said Humira will remain preferred and Amjevita will be placed on a non-preferred brand tier.
Mark Cuban’s Pharmacy Teams up With Cancer Health App
Mark Cuban’s Pharmacy Teams up With Cancer Health App
Mark Cuban’s Pharmacy Teams up With Cancer Health App
January 30, 2023
The collaboration between Cost Plus Drugs and OncoPower provides access to generic medications for patients with cancer integrated with OncoPower’s Pill Reminder tool.
Senators Reintroduce PBM Legislation
Senators Reintroduce PBM Legislation
Senators Reintroduce PBM Legislation
January 30, 2023
The proposed legislation, sponsored by Sens. Chuck Grassley and Maria Cantwell, aims to increase transparency of PBM business practices.
FDA Approves Orserdu to Treat Metastatic Breast Cancer
FDA Approves Orserdu to Treat Metastatic Breast Cancer
FDA Approves Orserdu to Treat Metastatic Breast Cancer
January 30, 2023
Elacestrant, now with the brand name Orserdu, is an oral selective estrogen receptor degrader (SERD), which works by blocking the effects of estrogen on hormone receptor-positive breast cancer cells.
<1
...
252627282930313233
...
229>
© 2025 MJH Life Sciences

All rights reserved.